Skin rash in metastatic hormone sensitive prostate cancer patients treated with apalutamide: a retrospective multicenter study in Korea

In a real-world cohort of Korean patients, skin rash occurred in 36.4% of cases, with a median time to onset of 65.5 days. Grade 3 skin rash developed in 10.3% of cases. While MLR and SIRI were significantly higher in the G2 plus G3 group, these markers cannot be considered reliable predictors due to a low area under the curve (AUC < 0.7) before apalutamide treatment. However, increased levels of PLR, SII, and SIRI could potentially be useful for monitoring for the risk of severe rash development in these patients.

Authors

Institutions

Publication Details

Journal
Prostate International
Published
2024-11-05
DOI
https://doi.org/10.1016/j.prnil.2024.10.003
Citations
4
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
1.68

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Skin rash in metastatic hormone sensitive prostate cancer patients treated with apalutamide: a retrospective multicenter study in Korea

Hongzoo Park, Jae Il Chung, Byung Hoon Kim, Tae Gyun Kwon et al.
4 citations
Prostate International
Prostate Cancer Treatment and Research
1.68
article

Skin rash in metastatic hormone sensitive prostate cancer patients treated with apalutamide: a retrospective multicenter study in Korea

Hongzoo Park, Jae Il Chung, Byung Hoon Kim, Tae Gyun Kwon, Jae Young Joung, Kyo Chul Koo, Byung Ha Chung, Taek Won Kang, S.H. Yu, U‐Syn Ha, Joongwon Choi, Seok Joong Yun, Jong Wook Park, Yun‐Sok Ha, Sung Kyu Hong, Jung Ki Jo, Hwang Gyun Jeon, Seong Il Seo, Hyun Ho Han, Jun Nyung Lee, Chan Ho Lee, Sungchan Park, Won Tae Kim, Jong Wook Kim, Won Ik Seo, Hak Min Lee, Soo Dong Kim, Ji Youl Lee
article en
4 citations

Abstract

In a real-world cohort of Korean patients, skin rash occurred in 36.4% of cases, with a median time to onset of 65.5 days. Grade 3 skin rash developed in 10.3% of cases. While MLR and SIRI were significantly higher in the G2 plus G3 group, these markers cannot be considered reliable predictors due to a low area under the curve (AUC < 0.7) before apalutamide treatment. However, increased levels of PLR, SII, and SIRI could potentially be useful for monitoring for the risk of severe rash development in these patients.

Prostate InternationalVol. 13(1)
Ulsan College (KR), Kangwon National University (KR), Yonsei University (KR), Korea University Medical Center (KR), Samsung Medical Center (KR), Seoul National University Bundang Hospital (KR), Kyungpook National University (KR), University of Ulsan (KR), Chonnam National University Hospital (KR), Inje University Busan Paik Hospital (KR), National Cancer Center (KR), Ulsan University Hospital (KR), Chung-Ang University Hospital (KR), The Catholic University of Korea Seoul St. Mary's Hospital (KR), Chungbuk National University Hospital (KR), Hanyang University (KR), Dong-A University (KR), Keimyung University (KR), Sungkyunkwan University (KR), Catholic University of Korea (KR)
National Research Foundation, Ministry of Education, National Research Foundation of Korea
Good health and well-being
Openalex Percentile: Top 14%
Prostate Cancer Treatment and Research
1.68
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.